Lupin has received final approval from USFDA to market its generic version of Mylan’s triamcinolone acetonide cream used for treatment of skin disease. The approval is for multiple strengths of 0.025 per cent, 0.1 per cent and 0.5 per cent triamcinolone acetonide cream which is prescribed for relief from inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Company Profile : Lupin Ltd
Leave a Reply